Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
R/S..no doubt about it despite the bs Reaping keeps spewing. Typical and an on-going tactic of OTC companies and ONCX is no different. IT'S THE ONLY WAY FOR ONCX TO REACH IT'S GOAL OF NASDAQ LISTING...NO OTHER WAY. R/S WILL NOT PUT ONCX OR GRENNVILLE HOSPITAL AT RISK OF LOSING IT'S MAJORITY POSITION.
Hahaha...notice anything different in the last year?
August 2018
Note 3 - Stockholders’ Deficit
We have 8,000,000,000 authorized shares of Common Stock, $0.0001 par value, and 250,000,000 authorized shares of preferred stock, of which 150,000,000 are designated as Series A Preferred Stock, $0.0001 par value. As of June 30, 2018, 104,477,936 shares of Common Stock were issued and outstanding, and 63,038,284 shares of Series A Preferred Stock, convertible into 105,297,802 shares of Common Stock, were issued and outstanding.
In addition, as of June 30, 2018, we have outstanding options to acquire up to 6,800,000 shares of Common Stock, warrants to acquire up to 49,477,380 shares of Series A Preferred Stock (which upon exercise would be convertible into 82,645,958 shares of Common Stock) and warrants to acquire up to 251,513,750 shares of Common Stock. We may issue an additional 224,123,951 shares of Common Stock if holders of secured notes voluntarily convert. If all derivative and convertible securities were fully exercised and converted into Common Stock, there would be a total of 774,859,397 shares of Common Stock outstanding. In addition, we may be obligated to issue an additional 14,000,000 shares of Series A Preferred Stock in exchange for future clinical research services in the amount of $1,050,000.
October 2017
Note 3 - Stockholders’ Deficit
We have 950,000,000 authorized shares of Common Stock, $0.0001 par value, and 250,000,000 authorized shares of preferred stock, of which 150,000,000 are designated as Series A Preferred Stock, $0.0001 par value. As of September 30, 2017, 103,878,536 shares of Common Stock and 63,038,284 shares of Series A Preferred Stock were issued and outstanding. The shares of Common Stock include the 31,766,503 shares held by the remaining shareholders of Oncolix prior to our acquisition of control on April 8, 2017.
In addition, as of September 30, 2017, we have outstanding options to acquire up to 6,800,000 shares of Common Stock, warrants to acquire up to 49,477,380 shares of Series A Preferred Stock and warrants to acquire up to 64,660,120 shares of Common Stock. In addition, we may be obligated to issue an additional 14,000,000 shares of Series A Preferred Stock in exchange for future clinical research services, and we may issue an additional 55,872,837 shares of Common Stock if holders of secured notes voluntarily convert.
Noteholders are drooling. R/S. Convert at .03-.05, sell at 1.00+.
And update the info above. It looks like shit and is older than dirt.
Lot of ask slappin goin on...wonder why??????
Results of the trials will prove Oncolix has a viable product, nothing else matters. The fact that the same investors twice threw their money into the Oncolix kitty means nothing.
Don't kid yourself, the majority of bio-tech companies fail and most of them had investors who thought they were investing in a product worth investing in, just like Oncolix has.
Don't get your underwear in a bunch yet or go buy a yacht, terms of the agreement have not been disclosed yet.
Lack of news and/or communication from this company is an obvious message that they can give a rat's ass about their shareholders.
Fireworks tomorrow!!!!!
More like vasoline mixed with sand!!!!
Yep, news soon, or maybe later, but if not later then news sooner than later, but definitely news sometime between now and the end of the year, but if no news this year then news will come next year.
Incorrect, 20 calendar days started on or about May 4th, so r\s will happen any moment now.
Corporate Action amendment to the Company's Articles of Incorporation (the
"Amendment"), on April 23, 2018, by a vote of stockholders holding a majority of the
Company's voting power. The purpose of this Information Statement is to provide notice
that the Company’s majority stockholders, holding an aggregate of 262,809,108 votes,
representing 66.7% of the voting power of the Company as of the Record Date, executed
a written consent authorizing and approving the following corporate actions (the
“Corporate Action”):
1. The Reverse Stock Split;
2. The Name Change;
The adoption of the foregoing Corporate Actions will become effective 20 calendar days
after the mailing of this Information Statement. The Board of Directors is not soliciting
your proxy in connection with the adoption of these Corporate Actions and proxies are
not being requested from stockholders.
The Company is distributing this Information Statement to its stockholders in full
satisfaction of any notice requirements it may have under the Nevada Revised Statutes.
No additional action will be undertaken by the Company with respect to the receipt of
written consents, and no dissenters' rights with respect to the receipt of the written
consents, and no dissenters' rights under the Nevada Revised Statutes are afforded to the
Company's stockholders as a result of the adoption of this Corporate Actions.
Expenses in connection with the distribution of this Information Statement, will be paid
by the Company.
This Information Statement is being mailed on or about May 4, 2018 to all
Stockholders of record as of the Record Date.
Remember when many posted that they would "never" need to use 950,000,000 shares when it was authorized. Just a drop in the bucket compared to 8 billion....lol
One more more big thing to come!!!! Dilution....lol
Yep, big things coming indeed!!! Bankruptcy, lawsuits, new CEO, etc....lol
Great post!!!! Makes perfect sense.
Gotta love those 100 and 200 bids that someone places just to watch the pps significantly rise with so little effort.
Obviously, it's someone struggling to believe this pos is close to sinking and they are trying to keep everyone interested.
New CEO soon!!!!
Wait until the sinking ship is almost 100% underwater and then watch as someone will scoop up the leftovers at a fraction of what it would cost today to bail out Oncolix.
Don't hold your breath, the odds of obtaining the needed financing in the short timeframe is slim to none at this point.
Strange that the owner (Oncolix) of such a "legit science" is having financing issues and only $30,000 left in the bank account. I would think Redman would have investors lined up outside his office on a daily basis, but obviously that's not the case. Something is just not right or "legit".
Just started phase 1 and the science of Prolanta is legit?????? LOL!!! Hardly!!! Just a pipedream and has been for years. Let's see some results before we call it legit.
Fat lady is about ready to sing...lol
In a hurry to lose money???? Everytime there's been news in the past the pps drops....lol
Agree, time to empty the dirty bath water and fill with new.
Just got off the phone with Redscams...said he didn't have time to talk. He was in a hurry to get to the local pawn shop.....lol
Noteholders can get .0545/ps for a stock trading at .04/ps, but decided not too......lol, too funny.
8K changes nothing and making the assumption that financing is in the works is naïve. What other course of action did the noteholders have. Can't squeeze blood out of a turnip...lol
Just one, and one too many.....LOL!!!!!!!!!!!!
.02 by Wednesday. .01 by May. Bad news drop could come anytime.
No new revelations with the recent S-1. Standard stuff, more dilution, nothing more about Prolanta, etc....lol
August 2017 S-1 states same thing as recent S-1. Still begging for money to support a failed product and pyramid scheme.
What??? No green paint today??? Redscams Honda generator powering his laptop must have run out of gas today before close and he couldn't make it to the gas station and back to his tent in time.....LOL
Saw Redscams at the auto dealership yesterday. He was trading in his 1984 Buick Regal for a 1977 Gremlin. A little rusty like his tin cup....lol
Saw Redman at the last conference!!!!!!!! Had a nice two-person tent from Wal-Mart setup just outside the parking lot with an Oncolix sign attached to it, had a Honda generator running to power his TV and computer, and had one of those little propane grills that holds 2-3 hamburgers. His tin cup was a little rusty, but he still managed to get a few people to drop a few bucks into it....LOL
"Back" to .08-.10????? When was it ever at that price for more than a couple days except when and while it was dropping from .19 down to .03.....lol
Clinicals are a long way from being "off and running". They haven't reached the starting gate yet....lol
Dosing the second group has not yet started, the S1 would have stated it had if it had....lol
"We are a clinical-stage biopharmaceutical company developing medical therapies for the treatment of cancer. We commenced operations on January 24, 2007, and since 2008, our activities have been focused on the development of Prolanta™, a biological drug for the treatment of cancer. Our initial focus is ovarian cancer, and we commenced a Phase I clinical trial of Prolanta™ in the treatment of ovarian cancer after we received clearance from the FDA. We also believe that Prolanta™ may be effective in the treatment of breast, prostate and other cancers.
We believe our success primarily will be dependent on (i) the safety and efficacy of our drug candidate Prolanta in the treatment of ovarian and other cancers, (ii) our ability to retain and attract additional members of management, and (iii) our ability to raise sufficient capital to fund our development plans for Prolanta and/or acquire other product candidates. There are numerous other factors that will affect our success, such as competitive products, our ability to maintain a proprietary position, and the relative resources of others.
In early 2016, we commenced a Phase I clinical trial of Prolanta for the treatment of ovarian cancer. This trial will evaluate three dose-levels of Prolanta according to a protocol submitted to the FDA. We completed the first dosing group in June 2016, and our Data and Safety Monitoring Board (“DSMB”) has given us permission to dose a second group of patients with a higher dose of Prolanta. Dosing of this second group is expected to commence in 2018."
S1 dated 3/21/18 page 47
Wouldn't Redscam be better off if he walked up and down a busy intersection somewhere with a tin cup than to spend more money going to a worthless conference to beg for money???????